John Alexander Kelly net worth and biography

John Kelly Biography and Net Worth

Alex is Chief Financial Officer and has been with Precision BioSciences since October 2020 when he joined as Chief Corporate Affairs Officer. He joined Precision from Allergan, where he served as Executive Vice President, Corporate Affairs and Chief Communications Officer and President of The Allergan Foundation. In these roles, Alex developed internal and external messaging that shaped the company culture and supported several successful company transformations including the recent merger with AbbVie. Previously, Alex served as Senior Vice President, Chief Integration Officer for Actavis where he led back-to-back integration efforts for both the acquisition of Forest Labs and Allergan. Prior to this role, he was Senior Vice President, Chief Communications Officer, Public Affairs and Investor Relations at Forest Labs where he built a consolidated corporate communications and investor relations team and led integration efforts. Alex has held additional roles at Bausch + Lomb, Merck, Schering-Plough, Novartis, Pharmacia, and Pharmacia & Upjohn. He earned his Bachelor of Science in Pharmacy from Purdue University. When he is not working, Alex likes to spend time with his wife (preferably by a beach), attend his kid’s activities, garden, cook and run 100 miles every month.

What is John Alexander Kelly's net worth?: The estimated net worth of John Alexander Kelly is at least $1.05 million as of February 18th, 2026. Mr. Kelly owns 125,883 shares of Precision BioSciences stock worth more than $1,047,347 as of July 16th. This net worth evaluation does not reflect any other assets that Mr. Kelly may own. Learn More about John Alexander Kelly's net worth.
How do I contact John Alexander Kelly?: The corporate mailing address for Mr. Kelly and other Precision BioSciences executives is 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701. Precision BioSciences can also be reached via phone at (919) 314-5512 and via email at [email protected]. Learn More on John Alexander Kelly's contact information.
Has John Alexander Kelly been buying or selling shares of Precision BioSciences?: John Alexander Kelly has not been actively trading shares of Precision BioSciences during the last ninety days. Most recently, John Alexander Kelly sold 8,149 shares of the business's stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $3.84, for a transaction totalling $31,292.16. Following the completion of the sale, the chief financial officer now directly owns 125,883 shares of the company's stock, valued at $483,390.72. Learn More on John Alexander Kelly's trading history.
Who are Precision BioSciences' active insiders?: Precision BioSciences' insider roster includes Michael Amoroso (President & Chief Executive Officer), Melinda Brown (Director), Stanley Frankel (Director), Geno Germano (Director), Derek Jantz (Insider), Matthew Kane (CEO), John Kelly (CFO), and David Thomson (COO). Learn More on Precision BioSciences' active insiders.
Are insiders buying or selling shares of Precision BioSciences?: In the last twelve months, Precision BioSciences insiders bought shares 5 times. They purchased a total of 11,181 shares worth more than $53,978.57. In the last twelve months, insiders at the sold shares 8 times. They sold a total of 98,557 shares worth more than $407,257.82. The most recent insider tranaction occured on February, 18th when CEO Michael Amoroso sold 20,559 shares worth more than $78,946.56. Insiders at Precision BioSciences own 2.7% of the company. Learn More about insider trades at Precision BioSciences.
Information on this page was last updated on 2/18/2026.

John Alexander Kelly Insider Trading History at Precision BioSciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/18/2026	Sell	8,149	$3.84	$31,292.16	125,883
1/21/2026	Sell	15,213	$4.03	$61,308.39	106,448
11/3/2025	Sell	1,303	$6.49	$8,456.47	77,298
7/3/2025	Sell	14,827	$4.26	$63,163.02	73,485
12/27/2024	Buy	2,113	$4.75	$10,036.75	40,186
3/17/2023	Buy	666	$25.80	$17,182.80	8,187
9/22/2022	Buy	1,234	$40.20	$49,606.80	5,157
6/22/2022	Buy	1,126	$45.00	$50,670.00	3,923
3/17/2022	Buy	555	$92.40	$51,282.00

John Alexander Kelly Buying and Selling Activity at Precision BioSciences

Precision BioSciences Company Overview

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Today's Range

Now: $8.32

$8.20

$8.79

50 Day Range

MA: $7.39

$6.04

$9.28

2 Week Range

Now: $8.32

$3.53

$9.62

Volume

443,589 shs

Average Volume

335,996 shs

Market Capitalization

$214.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25